What is ALNY's health score?

ALNYLAM PHARMACEUTICALS, INC. (ALNY) has a TradeApes health score of 61 out of 100, rated Healthy. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is ALNY's estimated fair value?

Based on our 5-year discounted cash flow model, ALNYLAM PHARMACEUTICALS, INC.'s estimated fair value is $89.87 per share, representing a -67.8% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is ALNY undervalued or overvalued?

Our model currently rates ALNY as Overvalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

To Unlock Full Report

2 free score cards remaining

ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Healthcare Overvalued low healthy

$279.14

Updated: 2026-07-16

TradeApes Score

Financial Strength

75 Strong

Operating Trend

80 Strong

Relative Value

50 Mixed

Capital Allocation

20 Stressed

Risk Management

70 Healthy

Est. Fair Value $89.87

DCF Upside -67.8%

Sector Rank #5614 of 12118

Key Findings

+ Historically cheap — EV/EBITDA in bottom 25% of its 5-year range

Unlock Full Report →

− Extreme P/E — above 45×, very high expectations embedded in price

Unlock Full Report →

Industry Related Stocks

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Aardvark Therapeutics, Inc. (AARD) Abivax S.A. (AAVXF) Ascend Wellness Holdings, Inc. (AAWH) AbbVie Inc. (ABBV) AbCellera Biologics Inc. (ABCL)

See all Healthcare stocks →

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.